Picard Medical Earnings Call Transcripts

Fiscal Year 2025

Earnings Call: Q4 2025
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 sales expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, positioning the therapy as the new standard of care for adult RRP.

Read full transcript →

Annual report
Earnings release
Slides
H.C. Wainwright 27th Annual Global Investment Conference

Picard Medical, via SynCardia, leads the total artificial heart market with the only FDA-approved device, strong clinical outcomes, and a focus on US and international expansion. Innovation efforts target a fully implantable heart by 2029, with ongoing label expansion and robust patient support.

Read full transcript →